Drugmaker Merck & Co. said that its third-quarter profit soared from results a year ago that were weighed down by huge acquisition and legal charges.
According to a study led by researchers from the Johns Hopkins Bloomberg School of Public Health, estimates of vaccination coverage can be improved by combining administrative data with survey data.
Cell Therapeutics Inc. resubmitted the pixantrone New Drug Application to the U.S. Food and Drug Administration's Division of Oncology Drug Products for accelerated approval to treat relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed prior therapy.
Bristol-Myers Squibb and Gilead Sciences announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing its protease inhibitor Reyataz and Gilead’s cobicistat.
Despite vast differences in the genetic code across individuals and ethnicities, the human brain shows a “consistent molecular architecture,” say researchers supported by the National Institutes of Health.
Xoma Ltd. and Aragen Bioscience Inc. entered into an agreement under which Aragen Bioscience will provide its clients access to Xoma’s human engineering technology for antibody humanization.
Emerald BioStructures announced a three-year extension of its ongoing collaboration with UCB.
Almac has established a mass spectrometry laboratory in their European Headquarters, Craigavon, United Kingdom.
Control Company’s Traceable digital hygrometer/thermometer/dew point instrument provides a response time of under 10 seconds with a resolution of 0.01% RH, 0.01°F/°C, and 0.01° dew point °F/°C.
The arium pro from Sartorius Stedim Biotech provides ultrapure water for analytical applications like atomic absorption, ion exchange chromatography and inductively coupled plasma mass spectrometry.
Hamilton Storage Technologies and Robotics have delivered and successfully installed an integrated compound management system at Boehringer Ingelheim's Research and Development Centre.
Activartis GmbH is developing a cancer immunotherapy concept which is currently in Phase 2 clinical trials. The Activartis platform focuses on dendritic cells, the key regulatory elements of the immune system.
Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 17% in the third quarter, chiefly spurred by strong sales of its new diabetes drugs.
Pfizer Inc.'s blockbuster vaccine against dangerous bacterial infections has been approved in Europe for use in adults age 50 and older, the drugmaker announced.